Use of magnesium orotate in children with myocardial hypertrophy in the presence of arterial hypertension
Abstract
The article provides a comparative analysis of the antihypertensive and cardioprotective effects of magnerot® on pathological cardiac remodeling and repolarization in children with sustained hypertension complicated by left ventricular hypertrophy. Stress testing before and after combined therapy with angiotensin-converting enzyme inhibitors and magnerot® revealed higher exercise tolerance and a normalized blood pressure response in hypertensive children with left ventricular hypertrophy. Moreover, there was a reduction in the spatial dispersion of repolarization. These results substantiate the need to incorporate magnerot® in combination with angiotensin-converting enzyme inhibitors into therapy for patients with hypertension complicated with left ventricular hypertrophy.
About the Authors
V. V. Linyaeva
Research Clinical Institute of Pediatrics, Moscow
Russian Federation
Russian Federation
I. V. Leontyeva
Research Clinical Institute of Pediatrics, Moscow
Russian Federation
Russian Federation
References
1. Gersh B.J., Maron B.J., Bonow R.O. Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation. American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124: 1304—1377.
2. Danlof B., Devereux R.B., Kieldsen S.E. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995—1003.
3. Walter T., Griessl G., Kluge P., Neugebauer A. Q—T dispersion in surface ECG and Q—T dynamics in long-term ECG in patients with coronary heart disease in the chronic postinfarct stage with and without ventricular tachyarrhythmias — correlation with other risk parameters. Z Kardiol 1997; 86: 204—210.
4. Ichkhan K., Molnar J., Somberg J. Relation of left ventricular mass and Q—T dispersion in patients with systemic hypertension. Am J Cardiol 1997; 79: 508—511.
5. Горбуновa И.А. Влияние дозированной физической нагрузки на процессы адаптации и дизадаптации сердечно-сосудистой системы у детей и подростков в норме и при патологии: Автореф. дис. … канд. мед.наук. Саранск 2009; 16.(Gorbunova I.A. Graduated exercise influence on the processes of adaptation and disadaptative cardiovascular system in children and adolescents in health and disease: Authoref. dis. ... Cand. Sciences. Saransk 2009; 16.)
6. Макаров Л.М. Холтеровское мониторирование. М: Мед-практика-М 2008; 544. (Makarov L.M. Holter monitoring. Moscow: Medpraktika-M 2008; 544.)
7. Меерсон Ф.З., Пшенникова М.Г. Адаптация к стрессорным ситуациям и физическим нагрузкам. М: Медицина 1988;252. (Meerson F.Z., Pshennikova M.G. Adaptation to stress situations and physical activities. Moscow: Medicine 1988; 252.)
8. Corrado D., Basso C, Thiene G. Arrhythmogenic right ventricular cardiomyopathy: an update. Heart 2009; 95: 766-773.
9. Maron B.J. The 2006 American Heart Association classification of cardiomyopathies is the gold standard. Circ Heart Fail 2008; 1: 76.
10. Спасов А.А. Магний в медицинской практике. Волгоград: Отрок 2000; 268. (Spasov A.A. Magnesium in medical practice. Volgograd: Otrok 2000; 268.)
11. Школьникова М.А., Ерастова Е.К., Клейменова Н.И. Применение препарата магнерот® в детской кардиологической практике. Трудный пациент 2010; 1: 37—41. (Shkornikova M.A. Yerastova E.K., Kleymenova N.I. Use ofthe drug magnerot® in pediatric cardiology practice.
12. Trudniypacient2010; 1: 37—41.)
13. Балыкова Л.А., Ивянскш С.А., Урзяева А.Н. u др. Опыт применения метаболических кардиопротекторов в детской спортивной медицине. Рос кардиол журн 2011; 5: 52—57. (BalykovaL.A., Ivyanskiy S.A., UrzyaevaA. N. et al. Experience of using metabolic cardioprotectors in pediatric sports medicine. Ros cardiol zhurn 2011, 5: 52—57.)
14. Denise G., Sally A., Simons-Morton D.G. Nutrient Intake and Blood Pressure in the Dietary Intervention Study in Children. Hypertension 1997; 29: 930—936.
15. Коровина Н.А., Творогова Т.М., Гаврюшова Л.П. Применение препаратов магния при сердечно-сосудистых заболеваниях у детей. Лечащий врач 2006; 3: 4—6. (Korovina N.A., Tvorogova T.M., Gavryushova L.P Application of magnesium in cardiovascular diseases in children. Lechashiy vrach 2006; 3:4-6.)
Review
For citations:
Linyaeva V.V., Leontyeva I.V. Use of magnesium orotate in children with myocardial hypertrophy in the presence of arterial hypertension. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2014;59(3):71-76. (In Russ.)
Views:
1534
Email this article 